Metrics as of 10/17/2026, 06:36 AM (Berlin time), refresh in progress.
Omeros Stock
Omeros Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gregory A. Demopulos
- Employees
- 175
- Market cap
- $1.2 B
- IPO
- 08/10/2009
Omeros Corporation is a biopharmaceutical firm in the healthcare sector headquartered in Seattle, US. Established in 1994, the company is actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. Its therapeutic…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Omeros stock: price history
1D
-13.8%
1W
-18.3%
1M
-6.6%
6M
+20.5%
YTD
-5.7%
1Y
+64.8%
2Y
+291.3%
5Y
+109.6%
10Y
+120.7%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~62% stronger price swings than usual
Omeros stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Omeros Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of small-molecule and protein-based therapeutics. The company focuses on treating rare diseases, inflammatory conditions, cancers driven by immune system dysregulation, and addiction disorders. Its portfolio includes both commercialized products and an extensive clinical pipeline with compounds in Phases I through III, such as Narsoplimab for various indications in the complement system space. Beyond clinical development, the company maintains a broad preclinical program exploring new target structures in areas including oncology, CNS, and metabolic diseases.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Omeros
Analyst assessment of Omeros
PRICE TARGET LOW
US$22.00
CONSENSUS
US$27.50
MEDIAN
US$27.50
PRICE TARGET HIGH
US$33.00
1
STRONG BUY
11
BUY
5
HOLD
2
SELL
0
STRONG SELL
19
TOTAL · Buy
As of: 14/10/2026
Omeros stock metrics
P/E
8.48
P/B
-22.76
EV/EBITDA
9.43
RETURN ON EQUITY
-25.8%
NET MARGIN
46.4%
DEBT/EQUITY
-1.63
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.7%
FLOAT SHARES
69,285,955
AVG. DAILY VOLUME (30D)
1,392,833
Insider transactions (SEC)
Borges David J.
Borges David J.
Borges David J.
Borges David J.
Borges David J.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -13.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Omeros stock
What does Omeros do?
Omeros Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gregory A. Demopulos, the company employs around 175 people.
The IPO was on 08/10/2009; the stock trades on NASDAQ under the ticker OMER.
What do analysts say about Omeros stock?
19 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$27.50, ranging from US$22.00 to US$33.00, with a median of US$27.50.
This is an external assessment, not a statement by Market Jury.
When does Omeros report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 62% stronger than usual.
Does Omeros pay a dividend?
No, Omeros currently does not pay a dividend.
Which stocks are comparable to Omeros?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Omeros stock analyzed?
Clicking "Analyze stock" lets five strategies assess Omeros against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.